Shared on30 Jul 25Fair value Increased 23%
The consensus analyst price target for Insight Molecular Diagnostics has increased to $5.42, primarily reflecting improved revenue growth forecasts and a rising future P/E multiple. What's in the News The company changed its name from Oncocyte Corporation to Insight Molecular Diagnostics Inc.
Shared on01 May 25Fair value Decreased 51%
AnalystConsensusTarget has decreased revenue growth from 91.5% to 29.7%, decreased profit margin from 16.8% to 12.3% and increased future PE multiple from 84.2x to 179.4x.
Shared on24 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25Fair value Increased 66%
AnalystConsensusTarget has increased revenue growth from 32.1% to 91.5%, increased profit margin from 10.5% to 17.3%, decreased future PE multiple from 244.5x to 81.6x and decreased shares outstanding growth rate from 0.3% to 0.1%.